Project News Detail
| Project No : | 206349 |
|---|---|
| Project Title : | TheraNym Biologics to invest USD 175-mln in 60 KL bioreactor greenfield facility |
| Company Name : | Aurobindo Pharma Limited |
| Project Detail : | Aurobindo Pharma, through its subsidiary TheraNym Biologics, has announced plans to develop a greenfield manufacturing facility for large-scale mammalian drug substance production. The project, referred to as Unit 2, will house bioreactor capacities of up to 60 KL (60,000 litres), strengthening the company’s biologics manufacturing capabilities. TheraNym will invest approx. USD 150–175 million in the facility, which will include mammalian cell culture bioreactors along with advanced downstream purification infrastructure required for drug substance production. The development marks a significant expansion in the company’s biologics segment and aligns with growing global demand for complex biologic therapies. The project follows the signing of an additional product schedule under an existing contract manufacturing operations (CMO) agreement with Merck Sharp & Dohme Singapore. Under this arrangement, TheraNym will manufacture and supply products to MSD, further strengthening the strategic partnership initiated in 2024. This investment reinforces Aurobindo Pharma’s focus on high-value biologics manufacturing and positions it as a key player in the global contract development and manufacturing space. |
| Project Location : | Multi Location (Multi State) - Multi State - India |
| Project Estimation : | Refer Document |
| Status : | Announced |